Condition: Nasopharyngeal Carcinoma · Sponsor: Zhongshan People's Hospital, Guangdong, China
All participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab) et al. For all male participants and P85-Ab positive female participants, EBV DNA in plasma will be tested. Screening positive participants will be followed up annually. All subjects will also be followed by record linkage to Cancer Register and Population Register.
This description comes directly from the study's public registry record.
Mingfang Ji, MD · 86-760-89880417 · jmftbh@sina.com
Always discuss trial participation with your own doctor first.
| Zhongshan People's Hospital | Zhongshan, Guangdong, China | Recruiting |
| Wuzhou Red Cross Hospital | Wuzhou, Guangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04085900